Guangjun Fan

Mr. Guangjun Fan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
SWSi Wu
Si Wu
HBHansheng Bai
Hansheng Bai
LZLing Zhang
Ling Zhang
JHJiamin He
Jiamin He
XLXiangru Luo
Xiangru Luo
NSNa Sun
Na Sun
Background: The reported rate of cardiovascular adverse events (CAE) caused by immune checkpoint inhibitors (ICI) is low but potentially fatal. Assess the risk of CAE in cancer patients and compare the incidence of CAE between Chinese developed ICIs and imported ICIs.Methods: A retrospective analysis was performed on cancer patients treated with ICI for at least four cycles in the Second Affiliated Hospital of Dalian Medical University from January 2018 to March 2022. Baseline characteristics, physiological and biochemical values, electrocardiographic and echocardiographic findings were compared between patients with and without CAE.Results: Among 495 patients treated with ICIs, CAEs occurred in 64 patients (12.93%). The median time to the event was 105 days (61–202). The patients with low neutrophil-to-lymphocyte ratio (L-NLR) were significantly associated with the risk of developing CAE (hazard ratio HR 3.64, 95% confidence ratio CI 1.86–7.15, P = 0.000). Patients with higher comorbidity burden significantly increased the risk of developing CAE (HR 1.30, 95% CI 1.05–1.61, P = 0.014). Those who received a combination of ICI and vascular endothelial growth factor receptor (VEGFR) inhibitors (HR 2.57, 95% CI 1.37–4.84, P = 0.003) or thoracic radiation therapy (HR 32.93, 95% CI 8.81–123.14, P = 0.000) were at a significantly increased risk of developing CAE. Compared to baseline values, creatine kinase is -oenzymes (CK-MB) (95% CI -9.73 to -2.20, P = 0.003) and cardiac troponin I (cTnI) (95% CI -1.06 to -0.06, P = 0.028) were elevated, and the QTc interval prolonged (95% CI -27.07 to -6.49, P = 0.002). Using nivolumab as a control, there was no difference in CAE risk among the eight ICIs investigated. However, the results of the propensity matching showed that programmed death-ligand 1 (PD-L1) inhibitors had lower CAE occurrence compared with programmed cell death protein 1 (PD-1) inhibitors (adjusted HR = 0.38, P = 0.045).Conclusion: Patients who received concurrent VEGFR inhibitors and ICIs had a history of thoracic radiation therapy, L-NLR, and higher comorbidity burden had an increased risk of CAEs. Elevated cTnI, CK-MB, and QTc, can be used to monitor CAEs. There was no significant difference in CAE risks between Chinese domestic and imported ICIs. PD-L1 inhibitors had lower CAE occurrence than PD-1 inhibitors.

13 March 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
XLXiangru Luo
Xiangru Luo
SWShiyi Wang
Shiyi Wang
DLDong Li
Dong Li
JWJun Wen
Jun Wen
NSNa Sun
Na Sun
GFGuangjun Fan
Guangjun Fan
Objective: In critically ill patients, the change of pathophysiological status may affect the pharmacokinetic (PK) process of drugs. The purpose of this study was to develop a PK model for tigecycline in critically ill patients, identify the factors influencing the PK and optimiz dosing regimens.Method: The concentration of tigecycline was measured LC-MS/MS. We established population PK model with the non-linear mixed effect model and optimized the dosing regimens by Monte Carlo simulation.Result: A total of 143 blood samples from 54 patients were adequately described by a one-compartment linear model with first-order elimination. In the covariate screening analysis, the APACHEII score and age as significant covariates. The population-typical values of CL and Vd in the final model were 11.30 ± 3.54 L/h and 105.00 ± 4.47 L, respectively. The PTA value of the standard dose regimen (100 mg loading dose followed by a 50 mg maintenance dose at q12 h) was 40.96% with an MIC of 2 mg/L in patients with HAP, the ideal effect can be achieved by increasing the dosage. No dose adjustment was needed for Klebsiella pneumoniae for AUC0–24/MIC targets of 4.5 and 6.96, and the three dose regimens almost all reached 90%. A target AUC0–24/MIC of ≥17.9 reached 100% in patients with cSSSI in the three tigecycline dose regimens, considering MIC ≤ 0.25 mg/L.Conclusion: The final model indicated that APACHEII score and age could affect the Cl and Vd of tigecycline, respectively. The standard dose regimen of tigecycline was often not able to obtain satisfactory therapeutic effects for critically ill patients. For patients with HAP and cIAI caused by one of three pathogens, the efficacy rate can be improved by increasing the dose, but for cSSSI infections caused by Acinetobacter baumannii and K. pneumoniae, it is recommended to change the drug or use a combination of drugs.

8 March 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
YJYan Jiang
Yan Jiang
HBHan-Sheng Bai
Han-Sheng Bai
GLGuo-Xin Liu
Guo-Xin Liu
SWShi-Yi Wang
Shi-Yi Wang
LYLi Yin
Li Yin
GFGuangjun Fan
Guangjun Fan
Introduction: Global phase III clinical trials have shown superior hypoglycemic efficacy to insulin and other oral hypoglycemic agents. However, there is a scarcity of real-world data comparing different glucagon-like peptide 1 receptor agonist (GLP-1RA) directly. This study aimed to assess the safety and effectiveness of various GLP-1RA in treating type 2 diabetes mellitus (T2DM) in a real-world clinical setting and identify predictive factors for favorable treatment outcomes.Methods: This was a retrospective, single-center, real-world study. The changes in HbA1c, fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), and the percentage of participants who achieved HbA1c of <7%, 7%-8%, and ≥ 8% after GLP-1RA treatment was analyzed. The clinical factors that affect the effectiveness of GLP-1RA were analyzed.Results: At baseline, the 249 participants had a mean baseline HbA1c of 8.7 ± 1.1%. After at least three months of follow-up, the change in HbA1c was -0.89 ± 1.3% from baseline. Dulaglutide exerted a more significant hypoglycemic effect than immediate-release exenatide. The percentage of participants who achieved HbA1c<7% was substantial, from 6.0% at baseline to 28.9%. Average body weight decreased by 2.02 ± 3.8 kg compared to baseline. After GLP-1RA treatment, the reduction in SBP was 2.4 ± 7.1 mmHg from baseline. A shorter duration of diabetes and a higher baseline HbA1c level were more likely to achieve a good response in blood glucose reduction.Conclusions: This study provided real-world evidence showing that GLP-1RA significantly improved HbA1c, body weight, and SBP. The results can inform the decision-making about GLP-1RA treatment in daily clinical practice.

17 December 2024 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
YXYin Xiong
Yin Xiong
GLGuoxin Liu
Guoxin Liu
XTXin Tang
Xin Tang
BXBoyang Xia
Boyang Xia
YYYalian Yu
Yalian Yu
GFGuangjun Fan
Guangjun Fan
Background: In recent years, with the increase of antibiotic resistance, tigecycline has attracted much attention as a new broad-spectrum glycylcycline antibiotic. It is widely used in the treatment of complex skin and soft tissue infections, complex abdominal infections and hospital-acquired pneumonia by inhibiting bacterial protein synthesis. Tigecycline can exhibit significant time-dependent bactericidal activity, and its efficacy is closely related to pharmacokinetics. It can be evaluated by the ratio of AUC0-24 to the minimum inhibitory concentration (MIC) of pathogens. However, tigecycline may cause nausea, vomiting, diarrhea and a few patients have elevated serum aminotransferase, especially in critically ill patients. The safety of patients still needs further study.Methods: In this study, the clinical data of 263 patients with pulmonary infection in Shengjing Hospital of China Medical University and the Second Affiliated Hospital of Dalian Medical University were collected retrospectively, and the hepatotoxicity prediction model was established. The potential correlation between the toxic and side effects of tigecycline and the number of hospitalization days was preliminarily discussed, and the correlation analysis between the number of hospitalization days and continuous variables was established. Finally, the deep learning model was used to predict the hospitalization days of patients through simulated blood drug concentration and clinical laboratory indicators.Results: The degree of abnormal liver function was significantly correlated with AST, GGT, MCHC and hospitalization days. Secondly, the correlation between hospitalization time and clinical test indexes and simulated drug concentration was analyzed. It was found that multiple clinical laboratory parameters of patients (such as EO #, HCT, HGB, MCHC, PCT, PLT, WBC, AST, ALT, Urea), first dose (Dose), age and APACHE II score were significantly correlated with hospitalization days. The simulated blood drug concentration was correlated with the length of hospital stay from 12 h after administration, and reached the strongest between 24 and 48 h. The AUC of the liver function prediction model can reach 0.90. Further analysis showed that there was a potential correlation between hepatotoxicity and hospitalization days. The median hospitalization days of patients in the non-hepatotoxicity group, liver function injury group and hepatotoxicity group were 20, 23, and 30 days, respectively. Based on these results, the length of hospital stay was predicted by the deep learning prediction model with an error within 1 day.Conclusion: In this study, the hospitalization days of infected patients were predicted by deep learning model with low error. It was found that it was related to clinical test parameters, hepatotoxicity and dosage after administration. The results provided an important reference for the clinical application of tigecycline, and emphasized the need to pay attention to its toxic and side effects in use.

14 July 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YYYan Yang
Yan Yang
YHYuan Huo
Yuan Huo
DZDong Zhou
Dong Zhou
ZKZhijie Kang
Zhijie Kang
YHYanan Huang
Yanan Huang
JYJinsong Yan
Jinsong Yan
Introduction: Despite the increasing use of allogeneic hematopoietic stem cell transplantation (allo-HSCT), graft-versus-host disease (GVHD) remains the main cause of morbidity and mortality, significantly impacting HSCT outcomes. Steroids are the standard first-line treatment for acute GVHD (aGVHD); however, standardized treatment algorithms for patients who do not respond to steroid therapy are lacking. Ruxolitinib is the most promising second-line therapy for steroid-refractory (SR)-GVHD, but data on its first-line use for aGVHD are limited.Methods: In this retrospective study, we analyzed the data of 133 patients with aGVHD who underwent transplantation at our institution. Eighty-three patients received ruxolitinib combined with methylprednisolone, while 50 received methylprednisolone alone as the initial treatment.Results: The ruxolitinib/steroids group had a significantly higher overall response rate (ORR) on day 7 (86%) compared to the steroid-only group (68%; odds ratio [OR]=2.8, 95% confidence interval [CI]: 1.2–6.5, p=0.019). Similarly, ORR on day 14 was higher in the ruxolitinib/steroids group (92% vs. 79%; OR=2.7, 95% CI: 0.9–7.8, p=0.05). Although no statistical differences were observed in overall survival (OS), progression-free survival (PFS), and failure-free survival (FFS) between the two groups, patients who achieved early ORR on days 7 and 14 had better OS, PFS, and FFS. Additionally, in subgroup analysis of patients who underwent peripheral blood stem cell transplantations, the ruxolitinib/steroids cohort had significantly better OS (Hazard Ratio [HR]=0.34, 95% CI: 0.11–1.55, p=0.04), PFS (HR=0.37; 95% CI: 0.12–1.10, p=0.05) and FFS (HR=0.46; 95% CI: 0.19–1.11, p=0.05) compared to the steroid-only cohort. Adverse event (AEs) frequencies were comparable between groups, with the exception of neutropenia (32.5% vs. 12%, p=0.008) and CMV infection (34.9% vs. 18%, p=0.036), which were more frequent in the ruxolitinib/steroid group.Discussion: To the best of our knowledge, this is the first real-world study to demonstrate that adding ruxolitinib to a standard methylprednisolone regimen provides an effective and safe first-line treatment for aGVHD.

7 May 2021 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
LJLiu Jin
Liu Jin
XLXiangyang Liu
Xiangyang Liu
FRFeng Ren
Feng Ren
YLYonge Liu
Yonge Liu
NSNa Sun
Na Sun
GFGuangjun Fan
Guangjun Fan
Objective: This paper aims to assess the efficacy of tigecycline in the treatment of several different infections from a pharmacokinctic/phannacodynamic (PK/PD) perspective. Materials and methods: The minimum inhibitory concentration (MIC) test strip test was used to determine the MICs of clinical isolates of tigecycline. A 5,000-subjects simulation was performed by Crystal Ball software to calculate the probability of achieving the required PK/PD exposure. R_e z sults: The use of standard tigecycline dosing is predicted to have a good clinical outcome for patients suffering from complicated skin and skin structure infection (cSSSI) with MICs <= 0.25 mgxL(-1), patients suffering from complicated intra-abdominal infection (cIAI) with MICs <= 1 mgxL(-1), and patients suffering from hospital-acquired pneumonia (HAP) with MICs 0.5 mgxL(-1). Generally, Gram-positive bacteria are highly sensitive to tigecycline. while Gram-negative bacteria are less sensitive: for patients with HAP and cIAI, the tolerable outcome was achieved using the standard regimen for most Gramnegative pathogens; the desired outcomes could be obtained for the increased-dose treatment; with increasing dose (100 mg every 12 hours), the average cumlative fractions of response (CFRs) markedly increased from 38.18 to 56.21% for cSSSI patients. When tigecycline, a standard regimen, was used to treat carbapenem-resistant Klebsiella pneumoniae (CRKP) and carbapenemresistant Entembacter spp. (CRE) infections, the cumulative response scores were 4.96 - 66.39% and 13.14 - 95.18%, respectively, and the CFRs of the increased dose also increased correspondingly. Conclusion: Currently, the standard dose of tigecycline is feasible in the treatment of common bacterial infections, and PK/PD indexes are needed to optimize the regimens for refractory carbapenem-resistant bacterial infections. What is known about this subject - The use of standard tigecycline dosing is predicted to have a good clinical outcome for cSSSI patients with MICs <= 0.25 mgxL(-1), cIAI patients with MICs <= 0.5 mgxL(-1), and HAP patients with MICs <= 1 mgxL(-1) - Gram-positive bacteria are highly sensitive to tigecycline, while Gram-negative bacteria are less sensitive: their mean level of susceptibility to tigecycline is 77.3% (except Proteus mirabilis and Pseudomonas aeruginosa). - This may also warn that resistance of CRKP to tigecycline is worrying: for patients with cIAI and cSSSI, doses of 50 mg and 100 mg every 12 hours (q12h) did not achieve desirable results. In comparison, the prediction results for CRE infection are slightly improved: the dosing simulations confirmed that the current treatment, 50 mg q12h, was considered sufficient to treat HAP caused byCRE in cIAI patients. 100 mg q12h is recommended in clinical settings; however, for cSSSI treatment, combination regimen or other options for target elimination may be suggested. What this study adds - This article simulates the efficacy of different doses of tigecycline in the treatment of different infection sites from the PK/PD perspective and focuses on the sensitivity of common pathogens and CRE. Furthermore, current controversies about the dosage of tigecycline are partly explained in this article. We believe that the results of this study can provide guidance for the efficient use of tigecycline in clinical practice.